Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2018

Aug 14, 2018

SELL
$8.55 - $13.76 $564,300 - $908,160
-66,000 Closed
0 $0
Q1 2018

May 15, 2018

SELL
$8.99 - $14.95 $593,340 - $986,700
-66,000 Reduced 50.0%
66,000 $607,000
Q4 2017

Feb 14, 2018

BUY
$8.26 - $16.76 $454,300 - $921,800
55,000 Added 71.43%
132,000 $1.96 Million
Q3 2017

Nov 14, 2017

BUY
$5.1 - $9.55 $392,700 - $735,350
77,000
77,000 $720,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $415M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Precept Management LLC Portfolio

Follow Precept Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Precept Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Precept Management LLC with notifications on news.